AKTX

Akari Therapeutics Plc

9 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bullishMay 22

Secured $5.5 million in gross proceeds to fund working capital.

capital raise

60%

bearishMay 22

Issuance of multiple warrant series (H, I, J) creates significant future dilution risk.

dilution risk

70%

bearishMay 19

Net loss widened to $14.5 million due to massive non-cash impairments.

margin compression

90%

neutralMay 19

Reliance on a $25M ELOC with White Lion Capital as a primary liquidity backstop.

capital raise

60%

bearishMay 19

Received Nasdaq notice regarding minimum bid price compliance.

regulatory action

70%

bearishMar 30

Net loss of $17.3M with minimal cash runway creates an urgent need for dilutive capital.

margin compression

90%

neutralMar 30

Appointment of new CEO and interim CFO as part of a strategic operational reset.

management change

50%

bullishMar 30

Secured $25M ELOC with White Lion Capital to provide potential future funding.

capital raise

60%

bearishMar 30

Received Nasdaq notice regarding minimum bid price requirements with a May 2026 deadline.

regulatory action

80%

Filing History

8-KMay 22, 2026

Akari Therapeutics' 8-K filing details a $5.5 million offering consisting of ADSs, units, and various warrant series to support working capital. While the raise provides a necessary lifeline to extend the company's runway into mid-2026, it introduces a complex layer of potential dilution via Series H, I, and J warrants. Investors must now weigh the benefit of immediate solvency against the long-term impact of the warrant overhang and the company's ability to hit clinical catalysts before requiring further capital.

10-QMay 19, 2026

The 10-Q filing reveals a company at a critical crossroads, balancing a promising scientific pivot against a looming liquidity crisis. On one hand, the transition to a lean, AKTX-101-focused model and the engagement of WuXi Biologics suggest a viable path toward clinical validation. On the other hand, the 'going concern' warning and the massive impairment of assets from the Peak Bio acquisition indicate that the market has already priced in a high probability of failure. The overall impact of the filing is a high-risk, high-reward scenario where the company's survival depends entirely on its ability to secure capital in the next 90 days. If Akari can leverage its ASCO 2026 data to secure a strategic partner or a fresh equity infusion, the platform's novel biology could offer a massive upside. However, the current financial trajectory suggests a narrow window of opportunity before the cash runway expires.

10-KMar 30, 2026

Akari Therapeutics is currently a high-stakes bet on a novel mechanism of action within the ADC space. The filing highlights a company that has successfully streamlined its scientific focus but remains precariously underfunded. The transition to a 'virtual' manufacturing model and the aggressive reduction in overhead are necessary steps for survival, but they do not eliminate the fundamental risk of a pre-clinical biotech. Investors are essentially trading the probability of the PH1 payload's clinical success against a ticking clock of insolvency. The upcoming ADS ratio change and the May 2026 Nasdaq compliance deadline are critical near-term catalysts that will determine if the company can access the capital necessary to reach its 2027 clinical goals. The outcome depends entirely on whether the market assigns enough value to the preclinical data to support the necessary capital raises.